NCT06086197View on ClinicalTrials.gov

A-RGEMOX in the Treatment of Early Relapsed/Refractory DLBCL

PHASE2RecruitingINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

October 1, 2023

Primary Completion Date

October 1, 2025

Study Completion Date

October 31, 2026

Conditions
Diffuse Large B-cell Lymphoma RecurrentDiffuse Large B Cell Lymphoma Refractory
Interventions
DRUG

Anlotinib hydrochloride, Rituximab, gemcitabine, oxaliplatin

"Anlotinib: 12mg d1\~14 po qd, Rituximab: 375mg/m2 d1, gemcitabine: 1000mg/m2 d1 and d8, oxaliplatin: 130mg/m2 d1;~For subjects ≥75 years of age, appropriate reduction of chemotherapy drugs (not less than 75% of the standard dose, or withdrawal of day 8 gemcitabine) may be decided by the investigator."

Trial Locations (1)

310022

RECRUITING

Zhejiang Cancer Hospital, Hangzhou

All Listed Sponsors
lead

Zhejiang Cancer Hospital

OTHER